Inovio Pharmaceuticals, Inc. Co (AMEX: INO) (AMEX: INO) hoy puede pegar tirón fuerte para arriba
en premercado rebota...
+17%íšltima transacción: 1.11 1,11
Trade Time: Hora de la Transacción: Sep 10 10 de septiembre
Change: Variación: 0.00 (0.00%) 0.00 (0.00%)
Prev Close: Cierre anterior: 1.11 1,11
Open: Apertura: N/A N / A
Bid: Oferta: 1.13 x 10000 1,13 x 10000
Ask: Pregunte: 1.40 x 1000 1,40 x 1000
1y Target Est: Objetivo Estimado en 1: 2.93 2,93
Day's Range: Rango del día: N/A - N/A N / A - N / A
52wk Range: 52wk Rango: 0.76 - 1.99 0,76 a 1,99
Volume: Volumen: 7,000 7.000
Avg Vol (3m) : Vol. medio (3m): 483,645 483.645
Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18. This vaccine targets HPV E6 and E7 proteins and is delivered via in vivo electroporation. All dose groups developed significant antibody and T-cell immune responses; however, more notably, in the third and final dose group, five of six (83%) patients developed unprecedented T-cell responses not achieved by any other non-replicating vaccine platform in humans. Inovio is planning to start a Phase II clinical study in the first quarter of 2011.
Read more:
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=27637&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Pharmaceutical-News+%28PharmiWeb+-+Pharmaceutical+News%29#ixzz0zPGfRceX
